Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag China's drug regulator accepts application for pimicotinib, a new treatment for a rare tumor.

flag Shanghai-based Abbisko Therapeutics announced that China's NMPA has accepted the New Drug Application for pimicotinib, a CSF-1R inhibitor for treating Tenosynovial Giant Cell Tumor (TGCT). flag Clinical trials showed significant improvements in patient outcomes. flag The drug received Priority Review, expected to expedite its approval process. flag Merck has global commercial rights to pimicotinib.

10 Articles

Further Reading